Goldman Sachs has issued a research report stating that WuXi AppTec (02359) held its annual investor day on November 6, with the overall content of the event aligning with the bank's expectations. The company further demonstrated progress in technological capabilities, R&D pipeline, and operational efficiency, while making no updates to its financial forecasts. The bank maintains a "Buy" rating on WuXi AppTec with a target price of HK$251.
The report noted that company management provided details confirming the view that AIDD (AI-empowered scientific research) does not replace traditional R&D services but rather expands the scope of drug discovery by generating more biological hypotheses and exploring new targets and molecular modalities, thereby lowering the barriers to innovation. At the same time, faster design and analysis cycles will increase demand for physical "make and test" steps. WuXi AppTec's ability to integrate chemistry, biology, and drug metabolism (DMPK) serves precisely as the wet lab component in this model, converting computational hypotheses into actual compounds and experimental data at scale.
Management illustrated that one AIDD client's analytical throughput demand reached approximately 10 times that of traditional small molecule projects, while another global AI company requested 5,000 culture plates, equivalent to roughly 500 times the throughput of a traditional project. WuXi AppTec also showcased its automation and round-the-clock bioanalysis and high-throughput ADME (drug metabolism and pharmacokinetics) capabilities. The company manages a system of over 1 million compounds as well as a virtual compound library with a scale of 46 billion.
Goldman Sachs specifically highlighted a serial entrepreneurial team from California that does not have its own laboratory. Through collaboration with multiple early-stage platforms of WuXi AppTec, the team's projects expanded from 4 to more than 40, demonstrating how the company deepens client relationships and expands market share through early-stage engagement.
On operational efficiency, management stated that a new workshop now requires only about two months from startup to full production, a significant reduction compared to the past. Workshop construction time has also been shortened from the previous 2 to 3 years to approximately 14 months. Currently, about 20 workshops are in the delivery, construction, or planning stages. The company adopts a "build, deliver, and use simultaneously" strategy, allowing capacity expansion to better align with project progress. The new Changzhou base plans to invest 10 billion RMB to build 800 tons of API capacity within three years, with the first workshop expected to commence operations in mid-2028, with approximately 15 workshops planned in total.
Comments